Zimmer Biomet (NYSE:ZBH) Price Target Lowered to $105.00 at Stifel Nicolaus

Zimmer Biomet (NYSE:ZBH) had its price objective reduced by Stifel Nicolaus from $110.00 to $105.00 in a report issued on Wednesday morning, MarketBeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other analysts also recently issued reports on the company. Leerink Partners initiated coverage on Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. UBS Group reissued a “sell” rating and set a $89.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, February 11th. William Blair initiated coverage on Zimmer Biomet in a research report on Friday, February 20th. They set a “market perform” rating for the company. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. Finally, BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $102.43.

Zimmer Biomet Stock Down 3.0%

NYSE ZBH opened at $80.31 on Wednesday. Zimmer Biomet has a 52 week low of $79.83 and a 52 week high of $108.29. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The business’s fifty day simple moving average is $92.87 and its 200-day simple moving average is $92.81. The firm has a market cap of $15.54 billion, a PE ratio of 22.69, a P/E/G ratio of 1.89 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the previous year, the firm earned $1.81 EPS. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts anticipate that Zimmer Biomet will post 8.39 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is currently 27.12%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors have recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at about $204,000. Sivia Capital Partners LLC acquired a new position in Zimmer Biomet in the 2nd quarter valued at about $232,000. United Bank grew its position in Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after acquiring an additional 1,153 shares in the last quarter. Federated Hermes Inc. grew its position in Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after acquiring an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC grew its position in Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after acquiring an additional 37,116 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 results beat and guidance raised — Zimmer Biomet reported adjusted EPS of $2.09 (vs. $1.86 est.), revenue of ~$2.09B (beat) and organic sales growth; the company updated FY2026 adjusted EPS guidance to $8.40–8.55. These operational beats and the guidance raise are supportive for longer‑term fundamentals. PR Newswire: Q1 Results
• Neutral Sentiment: Conference call / transcripts are available and highlight the company’s growth drivers and margin expansion; these give investors more detail on product momentum and the salesforce shift but have not calmed near‑term volatility. Earnings Call Highlights
• Negative Sentiment: Finance leadership turnover — CFO Suketu Upadhyay departed and an interim CFO was named; reports link the exit to a sharp intraday selloff and said the stock plunged to multi‑year lows on the news. Leadership uncertainty in the finance function is a clear near‑term negative. CFO Transition (PR Newswire) Article: Stock Plunges
• Negative Sentiment: Analyst price‑target cuts and mixed ratings — multiple firms trimmed targets (examples: JPMorgan $100→$95, Wells Fargo $98→$90, Stifel $110→$105, Truist trimmed its PT to $92) which lowers street support levels and can amplify selling pressure. Benzinga: Analyst Notes The Fly TickerReport
• Negative Sentiment: Technical / market context — the stock is trading with elevated volume, underperforming peers and around its 52‑week low, increasing the likelihood of momentum-driven downside until leadership/catalysts stabilize. MarketWatch: Underperformance

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.